Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
>
Regulatory
Regulatory
Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board
Kancera AB changes name to Novakand Pharma AB
Kancera initiates process to seek stakeholders for a reverse take over
Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851
Kancera terminates letter of intent with Recardio
Kancera reports positive top-line results from the KANDOVA study
Kancera reports positive outcome of pre-IND meeting with FDA
Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
Kancera changes Certified Adviser to Redeye AB
Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145
